You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Xalkori

Showing 1 - 25 of 45
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Rockville (Crizotinib - Usual, Crizotinib - Study)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Crizotinib - Usual
  • Crizotinib - Study
  • Rockville, Maryland
    Medicine Invention Design, Inc. - IORG0007849
Aug 15, 2023

Safety and Efficacy of Xalkori ROS1

Recruiting
  • Non-small Cell Lung Cancer
  • Tokyo, Japan
    Pfizer local country office
Aug 26, 2021

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

Active, not recruiting
  • ALK or ROS1-positive NSCLC
  • Fuzhou, Fujian, China
  • +9 more
Aug 30, 2022

Metastatic Uveal Melanoma Trial in Grand Rapids (IDE196, Crizotinib, Pembrolizumab)

Recruiting
  • Metastatic Uveal Melanoma
  • Grand Rapids, Michigan
    The Cancer and Hematology Centers
Aug 14, 2023

Advanced Cancers Trial in Houston (Crizotinib, Dasatinib)

Completed
  • Advanced Cancers
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jun 29, 2022

Advanced Cancers Trial in Houston (Crizotinib (Xalkori), Pazopanib, Pemetrexed)

Terminated
  • Advanced Cancers
  • Crizotinib (Xalkori)
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 3, 2021

Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)

Active, not recruiting
  • Hematologic Cancers
  • +2 more
  • Villejuif, Ile De France, France
    Gustave Roussy
Sep 5, 2022

Endometrial Cancer Recurrent Trial in Tainan (Crizotinib 250 MG)

Recruiting
  • Endometrial Cancer Recurrent
  • Crizotinib 250 MG
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Jun 6, 2022

NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Avitinib Maleate
  • +13 more
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022

Lung Cancer, Nonsmall Cell Trial in Aurora (Crizotinib)

Completed
Has Results
  • Lung Cancer, Nonsmall Cell
  • Aurora, Colorado
    University of Colorado Denver
Jan 19, 2022

Castration-resistant Prostate Cancer Trial in Boston (Crizotinib, Enzalutamide)

Completed
  • Castration-resistant Prostate Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 5, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Feb 4, 2022

Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer Trial in United Kingdom (Crizotinib Oral Capsule

Recruiting
  • Lobular Breast Carcinoma
  • +3 more
  • Crizotinib Oral Capsule [Xalkori]
  • Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
  • Glasgow, United Kingdom
  • +7 more
Nov 1, 2021

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial in Houston (Axitinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2021

NSCLC Trial in Rockville (Crizotinib - Usual, Crizotinib - Study)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Crizotinib - Usual
  • Crizotinib - Study
  • Rockville, Maryland
    Medicine Invention Design, Inc. - IORG0007849
Oct 5, 2023

Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer Trial in Australia, Canada, United States (IDE196, Binimetinib,

Recruiting
  • Metastatic Uveal Melanoma
  • +3 more
  • Scottsdale, Arizona
  • +13 more
May 10, 2022

Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

Recruiting
  • Lung Cancer
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 7, 2021

NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Augusta, Georgia
  • +40 more
Nov 29, 2023

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

Rare Tumor Trial (Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG)

Not yet recruiting
  • Rare Tumor
  • Almonertinib 110 MG
  • +10 more
  • (no location specified)
Jul 31, 2020

Crizotinib (Regulatory Post Marketing Commitment Plan)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • Crizotinib (Xalkori)
  • (no location specified)
Sep 12, 2019

Cancer, Tumors, Tumor Trial in Netherlands (Panitumumab, Olaparib, Dabrafenib)

Recruiting
  • Cancer
  • +3 more
  • Amersfoort, Utrecht, Netherlands
  • +34 more
Oct 26, 2021

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC Trial in Worldwide (PF-06463922, Crizotinib)

Active, not recruiting
Has Results
  • ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
  • Fayetteville, Arkansas
  • +71 more
Feb 16, 2022

NSCLC Trial in Worldwide (X-396 (ensartinib), crizotinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Phoenix, Arizona
  • +122 more
Oct 21, 2022